225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skippingL. De Waele, M. Guglieri, Perry B. Shieh et al.|Neuromuscular Disorders|2024Cited by 1
686VPThorough QT study on the effect of therapeutic and supratherapeutic dosing of givinostat in healthy volunteersTracey Willis, S. Cazzaniga, J. Bourke et al.|Neuromuscular Disorders|2025Cited by 0
656PSustained functional improvement with DYNE-251 in males with DMD mutations amenable to exon 51 skipping enrolled in the phase 1/2 DELIVER trialM. Guglieri, Douglas S. Kerr, Craig Campbell et al.|Neuromuscular Disorders|2025Cited by 0